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ABSTRACT

THE DEVELOPMENT OF VDR-COACTIVATOR INHIBITORS
AND THEIR EVALUATION USING BIOCHEMICAL AND
CELL-BASED ASSAYS
by
Belaynesh D Feleke
The University of Wisconsin-Milwaukee, 2014
Under the Supervision of Professor Alexander Arnold, PhD

The vitamin D receptor (VDR) belongs to the family of nuclear receptors and plays a
crucial role in many biological processes such as cell differentiation, cell proliferation
and calcium homeostasis. VDR is a good pharmaceutical target for many diseases
including cancer, metabolic disorders, skin diseases and cardiovascular diseases. Upon
binding with its endogenous ligand calcitriol in the body, VDR undergoes a
conformational change that disrupts the interaction with corepressor proteins and instead
enables the interaction with coactivator proteins that mediated transcription. The goal of
the research is the development of new small molecules that will selectively inhibit the
interaction between VDR and coregulators by binding to the ligand binding site of VDR.
Eleven VDR antagonists were synthesized based on GW0742 a potent PPARδ agonist
that inhibit VDR-mediated transcription at higher concentrations. The compounds were
evaluated using cell-based and biochemical assays to determine their ability to inhibit the
interaction between VDR and steroid receptor coactivator-2 (SRC-2) and to determine
ii

the ability to activate PPARδ mediated transcription. BF040813F and BF090813A1 were
the most active compounds towards VDR without activating PPARδ. The simple
accessibility of BF040813F, being a precursor compound, makes it an attractive
candidate for further SAR studies.
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CHAPTER I
1.

INTRODUCTION

The vitamin D receptor (VDR) is a transcription factor that belongs to the
superfamily of 48 nuclear receptors (NRs). As a member of nuclear receptors, it mediates
the transcription of genes responsible for cell differentiation, cell proliferation and
calcium homeostasis.[1]
VDR is also pharmaceutical target for several diseases including, skin diseases, hyperproliferative diseases, such as psoriasis, benign prostate hyperplasia, different types of
cancer, autoimmune diseases, microbial infections, and osteoporosis.
Nuclear receptors generally share a common structural organization (Figure 1).[2]
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Figure 1: General structure of nuclear receptor
The N-terminal domain is highly variable depending on the receptor and contains
a ligand-independent transactivation domain termed “Activation Function 1” (AF-1). The
most conserved central region of the nuclear receptors is the DNA-binding domain
(DBD) or the C domain, which is responsible for direct DNA interaction. Its main
function is to recognize and bind specific DNA regulatory sites called response elements
(REs). The flexible hinge, or D region, links the C-domain to the ligand-binding (E/F)
domain. The ligand binding domain of nuclear receptors comprises the ligand binding
pocket and also acts as a molecular switch by interpreting the ligand structure into
conformational changes converting the receptor into an activator or repressor. The LBD
remains the main feature that triggers biological responses to very diverse lipophilic
molecules. The F domain is located at the end C-terminus of NRs. Because of its high
variability in sequence, little is known about its structure and functional role.[3]

1.1

1, 25-Dihydroxyvitamin D3
The vitamin D hormone, 1, 25-dihydroxyvitamin D3 [1,25(OH)2D3], binds VDR

with high affinity (Figure 2).[4]
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Figure 2. Chemical structure of 1, 25-(OH)2D3.
Its precursor, Vitamin D (Figure 3), can be obtained through foods we eat or can

be synthesized from 7-dehydrocholesterol through photolysis occurring in the skin.[5]

Figure 3: Vitamin D formation and metabolism. [6]
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From there, the vitamin D binding protein shuttles vitamin D to the liver, where it
is hydroxylated at carbon 25 by vitamin D 25-hydroxylase, resulting in the formation of
25-hydroxyvitamin D3.[6] Vitamin D3 then binds to its binding protein and is transported
to the kidneys. In the kidneys, 25-hydroxyvitamin D3 is then hydroxylated at carbon 1 of
the A ring, which converts the vitamin D3 to the active form, 1, 25-dihydroxyvitamin
D3.[7] Vitamin D3 and its derivatives are metabolized in the presence of 24-hydroxylase
to 24-hydroxylated products and eventually forming calcitroic acid.[8, 9]

2.2 VDR-mediated transcription

In the nucleus, VDR binds DNA and forms a heterodimer with the retinoid X
receptor (RXR) (Figure 4). [10]

Cell

RXR
RxRE

VDR
VDRE

Figure 4: VDR-retinoid x receptor dimer in the absence of ligand.
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RXR is also a nuclear receptor and binds 9-cis retinoic acid.[11] In the absence of
the ligand, VDR is associated with corepressors such as the nuclear receptor corepressor
(N-CoR) and the silencing mediator of retinoic acid and thyroid hormone receptor
(SMRT).[12] N-CoR and SMRT are corepressor proteins that function to repress the
transcriptional activity of VDR. Ligand binding, on the other hand, permits VDRcoactivator interactions, and allows the formation of multi-protein complexes that
activate VDR-mediated transcription (Figure 5).

	
  

Coactivator Complex
corepressor
VDR

RXR

Polymerase

Transcription

Figure 5: Binding of a ligand enables VDR to perform transcription
In the presence of 1, 25-(OH)2 D3, the VDR-LBD undergoes a conformational change
which prevents corepressor binding and permits interactions with coactivator proteins
such as steroid receptor coactivator 2, resulting in the formation of a multi-protein
complex that activates VDR-mediated transcription. [13-15]
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1.3 VDR Antagonist

VDR, as stated earlier, is a pharmaceutical target for different disorders including,
cancer, skin disorder and autoimmune diseases. One way to modulate VDR-mediated
transcription is the development of small molecules that inhibit the interactions between
VDR and coregulators (corepressor and coactivators). Recently, VDR-coactivator
inhibitors have been introduced by other groups and us.[16-19] The inhibition of VDRcoregulator interactions has shown to selectively modulate the expression of specific
VDR genes. Most of the VDR antagonists developed are based on the secosteroidal
scaffold, which is very hydrophobic and metabolically less stable. Our research presented
herein, focuses on the introduction of non-secosteroidal VDR antagonists. These
compounds have to be selective towards VDR without binding to other NRs.
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CHAPTER II
2.

SYNTHESIS OF NEW VDR ANTAGONISTS

2.1. Introduction
A HTS campaign in collaboration with NIH investigating 390000 molecules led
to the identification of GW0742 (Figure 6) as a competitive VDR antagonist.[24]

Figure 6: Structure of compound GW 0742.
GW0742 was introduced by GlaxoSmithKline in 2003 as a highly selective
agonist for PPARδ.[25] Since then, compound GW0742 has been investigated in cellbased assays and in vivo, in order to understand the role of PPARδ in hypertension,
diabetes, inflammation, obesity, and cancer[26, 27]. Research by other groups and us has
shown that GW0742 inhibited the transcription of the VDR target gene, CYP24A1, in the
presence of 1,25-(OH)2D3.[28] It was determined that at micro molar concentrations
GW0742 behaved as an antagonist of VDR.[24]
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2.2. New proposed VDR antagonists

The approach for generating new selective and potent VDR antagonists involved
the variation of different parts of the GW0742 molecule (Figure 7).

F
F3C

CH3

N

S
S

OH
O

O

Figure 7: Different parts of the GW0742 molecule that were modified
The variation of the turquoise aryl moiety was carried out in collaboration with the NIH.
The analysis of the compounds and their corresponding potency towards VDR
antagonism and selectivity among nuclear receptors identified 2- and 3-methoxy as well
as 2- and 3-trifluoromethyl substituents as superior among 87 compounds tested. With
this in mind, we concentrated on the substitution of the thiazole moiety (yellow) with an
aryl ring system and concentrated on the connectivity between the two moieties as
depicted in Figure 8.
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Figure 8: New proposed VDR antagonists
The different connectivity of the proposed VDR antagonists introduces a range of
different angles. Our hypothesis is that this change will not only influence the affinity of
these compounds towards VDR but also change the selectivity towards other nuclear
receptors. Furthermore, we will introduce different substitutents especially 2- and 3methoxy as well as 2- and 3-trifluoromethyl substituents to optimize their potency.

2.3. Synthesis of proposed new VDR antagonists

2.3.1. Synthesis of 4-substituted VDR antagonists

10

The first step of the synthesis of the 4-substituted VDR antagonists started with the
reduction of the carboxylic acid 1.1 to make the alcohol 1.2 was realized in the present of
lithium aluminum hydride at 0°C in THF (Scheme 1). After a reaction time of 6 hours the
reaction was quenched with 1M HCl and the corresponding product was isolated in a
yield of 51%.

Figure 9: Synthesis of compound 1.6
The chloride 1.3. was formed with 1.2 in the presence of thionyl chloride.The
excess of SOCl2 was evaporated after 3 hours followed by evaporation at high vacuum
overnight giving 1.3 in 75% yield. The reduction of 1.1 in the presence of LiAlH4 also
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formed 2-methyl benzyl alcohol, which was separated by a high vacuum step from the
product by leaving it under high vacuum overnight. The chloride 1.3 is then coupled with
the phenol in the presence of Cs2CO3 to form the ester 1.4 in 66%. The product is
purified using column chromatography using a solvent gradient from 32% to 60% ethyl
acetate in hexanes. Suzuki coupling reaction was then used to form 1.4 with 4(Trifluoromethyl) phenyl boronic acid in the presence of Pd(PPh3)2Cl2 to form 1.5 which
is further hydrolyzed to the carboxylic acid final product 1.6.

2.3.2. Synthesis of 3-substituted VDR antagonists
The next analogue synthesis of the 3-substituted VDR antagonists started with the
reduction of the carboxylic acid 2.1 to make the alcohol 2.2 in the present of lithium
aluminum hydride at 0°C in THF (Scheme 2). After a reaction time of 6 hours the
reaction was quenched with 1M HCl and the corresponding product was isolated in a
yield of 51%. The chloride 2.3 was formed with 2.2 in the presence of thionyl chloride.
The excess of SOCl2 was evaporated after 3 hours followed by evaporation at high
vacuum overnight giving 2.3 in 75% yield. The chloride 2.3 is then coupled with the
phenol in the presence of Cs2CO3 to form the ester 2.4 in 66% yield. The product is
purified using column chromatography using a solvent gradient from 32% to 60% ethyl
acetate in hexanes. Suzuki coupling reaction was then used to form 2.4 with 2 methyl
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methoxy phenyl boronic acid in the presence of Pd(PPh3)2Cl2 to form 2.5. The ester was
further hydrolyzed to an acid in the presence of 8M NaOH to give 1.6.

Figure 10: Synthesis of compound 2.6.

2.3.3. Synthesis of 5-substituted VDR antagonists
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The next step of the synthesis of the 5-substituted VDR antagonists started with
the reduction of the carboxylic acid 3.1 to make the alcohol 3.2 in the present of lithium
aluminum hydride at 0°C in THF (Scheme 3). After a reaction time of 6 hours the
reaction was quenched with 1M HCl and the corresponding product was isolated in a
yield of 51%. The chloride 3.3 was formed with 3.2 in the presence of thionyl chloride.
The excess of SOCl2 was evaporated after 3 hours followed by evaporation at high
vacuum overnight giving 3.3 in 75% yield. The chloride 3.3 is then coupled with the
phenol in the presence of Cs2CO3 to form the ester 3.4 in 66%. The product is purified
using column chromatography using a solvent gradient from 32% to 60% ethyl acetate in
hexanes. Suzuki coupling reaction was then used to form 3.4 with 4-(Trifluoromethyl)
phenyl boronic acid in the presence of Pd(PPh3)2Cl2 to form 3.5 which is further
hydrolyzed to the carboxylic acid final product 3.6.
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Figure 11: Synthesis of compound 3.6.

2.4. Experimental section
The carboxylic acid 1.1 (4.0g, 18.6mmol) in anhydrous
THF (35mL) was added drop wise to LiAlH4 (0.88g,

15

23.19mmol) in anhydrous THF (44mL) at 0°C over 30 minutes. The resulting mixture
was slowly warmed to room temperature and stirred for 7 hours. The reaction was slowly
quenched with water (300mL) acidified to PH<2. The mixture was worked up with DCM
three times and was dried over Na2SO4.

The organic layer was concentrated to give a

white solid. The crude product 1.2 was left in the high vacuum over night and was used
in the next step without purification. 1HNMR (300MHz) (CDCl3) δ 7. 29(d, 1H); 7.14 (s,
1H,); 7.12 (1H, d); 4.51 (s, 2H); 2.25 (s, 3H).
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C NMR δ 19.84, 25.52, 67.91, 130.37,

135.53, 136.83, 172.16.

The alcohol 2.2 (2g, 9.95mmol) was
dissolved in Dichloromethane (4mL). Thionyl
chloride (1.6mL) was slowly added drop wise to
the above solution. The resulting mixture was
stirred at room temperature for 24 hours. The
organic solvent was removed using a rotary evaporator. The product 2.3 was then left
under high vacuum overnight. 1HNMR (300MHz) (CDCl3) δ 7. 38(d, 1H,); 7.36 (s, 1H);
7.21 (d, 1H); 4.57 (s, 2H); 2.45 (s, 3H). From the 13C NMR the peak at δ 138.60, 133.78,
132.68, 130.47, 128.56, 121.94, 43.19, and 17.8 confirmed the formation of the chloride.
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The

crude

benzyl

chloride 1.3 (1.5g, 6.83mmol)
and

the

phenol

(1.5g,

8.33mmol) were dissolved in
acetone (12mL) and treated with Cs2CO3 (0.6g). The reaction was stirred at 50°C for 16
hours. The reaction mixture was worked up with DCM three times and was dried over
Na2SO4. The organic layer was concentrated to give a while solid. The crude product 1.4
was purified by column chromatography with a solvent gradient from 32% to 60% ethyl
acetate in hexanes. The fractions were concentrated to a white solid. 1HNMR (300MHz)
(CDCl3) δ 7.39(s,1H,); 7.35 (1H,d, J=12);7.31 (d,1H,J=12); 7.17 (d,1H,J=9); 7.15(d, 1H,
J=9); 6.94(d,1H, J=9 ); 6.91 (d,1H,J=9);4.96 (s,2H); 3.7 (s, 3H); 2.96-2.91 ( t, 3H,J=6);
2.66-2.61 (t,2H J=6) ); 2.36, (s, 3H). 13C NMR δ 173.15, 166.43, 148.95, 138.67, 137.11,
135.30, 130.87, 130.05, 129.08, 121.47, 119.28, 51.69, 35.63, 30.35, 19.75.

Commercially

available

4-

(Trifluoromethyl) phenyl boronic acid
(100mg, mmol) and the ester 1.4
(51mg mmol) were suspended in
DMF (4mL) and water (200 µL).
PdCl2 (pph3)2

(10mg, mmol) was added followed by Cs2CO3 (292mg, mmol). The

resulting mixture was stirred in the microwave at 160 °C for 10 min. The mixture was
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acidified to PH<2. The reaction was worked up with DCM three times and dried over
Na2SO4. The crude product 1.4 was purified by column chromatography with a gradient
of 30% to 62% ethyl acetate in hexanes. The fractions were concentrated to a white solid.
1

HNMR (300MHz) (CDCl3) δ 7.41-7.28(m, 6H); 7.06 (s,1H); 7.04 (d,1H, J=9); 7.02(d,

1H, J=9); 6.99(d,1H, J=9 ); 6.94 (d,1H,J=9); 5.04 (s,2H); 3.7 (s, 3H); 2.97-2.92 ( t, 2H,
J=6 ); 2.72-2.67 (t , 2H J=6) ); 2.44 (s, 3H). 13C NMR δ 178.54, 157.62, 156.49, 138.59,
136.30, 133.51, 132.56, 131.56, 130.65, 129.26, 128.63, 128.41, 127.27, 120.80,
114.66,111.15, 68.56, 60.43, 55.51, 35.83, 29.04, 19.10.

The ester 1.5 is hydrolyzed to the carboxylic acid form. 1.5 (20mg) of the ester was
dissolved in THF (1.5mL). 8M NaOH
(0.15mL) was added and the resulting
mixture was stirred over night at room
temperature. The mixture was acidified to PH<2. The reaction was worked up with DCM
three times and dried over Na2SO4. The organic layer was concentrated to a white solid.
1

HNMR (300MHz) (CDCl3) δ 7.41-7.28 (m, 6H); 7.19-7.16 (m,2H); 7.04 (d,1H,J=9);

7.02(d, 1H, J=9); 6.99(d,1H, J=9 ); 6.94 (d,1H,J=9);5.07 (s,2H); 3.83 (s,3H) ; 2.97-2.92 (
t, 2H,J=6 );2.72-2.67 (t ,2H J=6) ); 2.44 (s, 3H).
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C NMR δ 176.22, 157.62, 156.49,

136.31, 133.51, 132.49, 131.56, 130.42, 130.85, 129.28, 128, 128.63, 127.26, 120.80,
114.86,111.15, 68.56, 55.53, 35.75, 29.52, 19.24.
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Compound 1.7 was synthesized using the same procedure as compound 1.6. A new
boronic acid was however used.
The hydroxyl group was found to
be active on a HTS with the NIH.
Therefore

(4-(hydroxymethyl)

phenyl) boronic acid was also used to couple with the 1.5 ester. Proton and Carbon NMR
confirmed the formation of this acid. 1HNMR (300MHz) (CDCl3) δ 7.50 (s, 1H); 7.49 7.35 (m, 6H); 7.21 (d,1H,J=9); 7.18(d, 1H, J=9); 6.98(d,1H, J=9 ); 6.95 (d,1H, J=9); 5.12
(s, 2H); 4.70 (s, 3H) ; 2.87-2.82 ( t, 2H, J=6 ); 2.60-2.55 (t, 2H,J=6) ); 2.44 (s, 3H). 13C
NMR δ 173.42, 157.36, 137 .38, 135.05, 133.08, 129.38, 129.27, 127.38, 225.73, 125.67,
124.92, 114.82, 68.27, 51.62, 35.98, 30.13, 19.08.

Compound 1.8 was also synthesized
the same way as compound 1.6 using a
different boronic acid. The trifluoro group
on the ring which was also on the
GWO742

molecule

and

has

shown

activity and hence was worth investigating. Therefore, 4-(Trifluoromethyl) phenyl)
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boronic acid was also coupled with the ester compound to give 1.8. 1HNMR (300MHz)
(CDCl3) δ 7.7 (m, 4H); 7.55-7.48 (m, 3H); 7.19 (d,1H, J=9); 7.16 (d, 1H, J=9); 6.96
(d,1H, J=9 ); 6.95 (d,1H, J=9); 5.09 (s, 2H); 3.7 (s,3H); 2.97-2.92 ( t, 2H,J=6 ); 2.67-2.64
(t, 2H J=6) ); 2.48 (s, 3H). 13C NMR δ 173.41, 157.35, 137.37, 135.06, 133.07, 129.33,
129.37, 129.27, 127.38, 225.71, 125.67, 124.92, 114.81, 68.20, 51.62, 35.97, 30.12,
19.08.

Reaction

scheme

2

was

performed the exact same way as
reaction

scheme

1.

The

corresponding NMR readings are
as

follows.

2.2:

1

HNMR

(300MHz) (CDCl3) δ 7. 527.00(m, 3H,); 4.6 (s, 2H); 2.35 (s,
3H). From the

13

C NMR the peak

at δ 61 confirmed the reduction to the alcohol. The crude NMR for 2.3 is as follows,
1

HNMR (300MHz) (CDCl3) δ 7. 59-7.04 (m, 3H,); 4.65 (s, 2H); 2.54 (s, 3H). From the
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C NMR δ 139.80 135.01, 130.98, 129.91, 127.81, 125.65, 43.76, 19.93. Peak 43.7

confirmed the formation of the chloride. Pure NMR for 2.4 was 1HNMR (300MHz)
(CDCl3) δ7.41- 6.94(m, 7H); 5.04 (s, 2H); 3.7 (s, 3H); 2.98-2.93 (t, 2H, J=6); 2.69-2.64
(t, 2H, J=6); 2.48 (s, 3H).

13

C NMR δ 173.15, 157.43, 148.95, 138.67, 137.11, 135.30,
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130.87, 129.05, 129.08, 118.60, 119.28, 68, 51.63, 35.97, 30.15, 18.73. NMR for 2.5:
1

HNMR (300MHz) (CDCl3) δ7.42-6.97(m, 11H); 5.11 (2H,); 3.79 (s, 3H); 3.70 (s, 3H),

2.97-2.91(t, 3H, J=6 3H); 2.67-2.64 (t, 2H J=6); 2.06 (s, 3H).

13

C NMR δ 174.17,

158.27,157.38, 142.10, 136.27,135.51, 133.56, 131.87,130.95,129.98, 129.38, 128.52,
126.14, 121.19, 115.53, 111.35, 69.85, 56.12, 52.33, 36.71, 30.85, 16.45
For 2.6 1HNMR (300MHz) (CDCl3) δ7.3-6.9 (m, 11H); 5.11 (2H,); 3.7 (s, 3H);
2.98-2.93 (t, 2H, J=6); 2.72-2.67 (t, 2H J=6); 2.17 (s, 3H).

13

C NMR δ 178.52,

157.63,156.65, 139.38, 135.56, 134.79,132.48, 131.16 , 130.81, 130.25, 129.27, 129.05,
128.66, 128.66, 127.98, 125.43, 120.48, 114.92, 110.62, 69.15, 55.42, 35.79, 29.79, 16.45

Reaction scheme 3 was also performed using the same procedures as reaction
scheme 1 (Figure 8). The
only difference being 5bromo-2-methyl benzoic acid
was

used

corresponding

instead.

The
NMR

readings are as follows. 3.2:
1

HNMR (300MHz) (CDCl3)

δ 7. 49(s, 1H,); 7.29-7.26 (d,
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1H, J=9); 7.01-6.98 (d, 1H, J = 9). 4.6 (s, 2H); 2.21 (s, 3H). 13C NMR δ 141.64, 134.44,
131.40, 129.61, 127.27, 125.49, 119.08, 61.96, 17.39. The peak at 61 confirmed that the
reduction had taken place. The crude NMR for 3.3 is as follows, 1HNMR (300MHz)
(CDCl3) δ 7. 49 (s, 1H,); 7. 48- 7.0 (m, 2H,); 4.64 (s, 2H); 2.4 (s, 3H).
137.56, 136.08, 131.76, 129.82, 128.97, 119.53, 43.90, 18.35. From the

13

13

C NMR δ

C NMR, the

peak around 43 confirmed the formation of the chloride. Pure NMR for 3.4 was 1HNMR
(300MHz) (CDCl3) δ7.6(s, 1H); 7.6-6.9 (m, 4H), 6.95 (m, 2H), 4.9 (s, 2H); 3.7 (s, 3H);
2.30-2.8 (t, 2H, J=6); 2.7-2.6 (t, 2H J=6); 2.32 (s, 3H). 13C NMR δ 173.38, 157.16,
137.23, 135.23, 133.24, 131.96, 131.03, 130.96, 119.62, 67.80, 51.62, 30.95, 18.43.
NMR for 3.5 1HNMR (300MHz) (CDCl3) δ 7.45 (s, 1H); 7.45-6.96 (m, 10H);
5.09 (s, 2H,); 3.8 (s, 3H); 3.70 (s, 3H), 2.97-2.92 (t, 2H, J=6); 2.67-2.44 (t, 2H J=6); 2.20
(s, 3H). 13C NMR δ 173.48, 157.55, 156.51, 136.32, 135.51, 134.49, 132.84, 130.81,
130.40, 130.18, 129.95, 129.27, 129.27, 128.54, 120.83, 114.85, 111.19, 68.88, 55.52,
51.00, 36.03, 30.16, 18.70. For 3.6: 1HNMR (300MHz) (CDCl3) δ7.35 (s, 1H); 7.35-6.95
(m, 10H); 5.08 (2H,); 3.8 (s, 3H); 2.97-2.91(t, 2H, J=6); 2.71-2.43 (t, 2H J=6) ; 2.4 (s,
3H). 13C NMR δ 178.71, 157.60, 156.49, 136.30, 135.50, 134.44, 132.48, 130.80, 130.39,
130.17, 129.26, 129.26, 128.52, 120.83, 114.95 , 111.05, 68.87, 55.51, 35.84, 29.79,
18.69.

22

CHAPTER III
3.

ASSAYS TO EVALUATE VDR ANTAGONISTS

3.1. Luminescence and detection
Luminescence is the emission of light due to the transition of electrons from
molecular orbitals of higher energy to those of lower energy, usually the ground state or
the lowest unoccupied molecular orbitals. When electrons return to a ground state from
being in an excited state, they release energy in the form of light (Figure 12).
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Figure 12: Schematic diagram depicting the generation of light from luminescent
molecules in the excited state

Luminescence is classified according to the excited state that gives rise to it and to the
source of the energy that caused the excited state to be populated with electrons. The
promotion of electrons to an excited state is called excitation. In many cases, this is
brought about by absorption of visible or ultraviolet radiation. In such a case, if
luminescence arises because electrons are relaxing from a singlet excited state to a singlet
ground state, then it is called fluorescence. If the excitation is the result of energy
released in a chemical reaction, the luminescence is called chemiluminescence. A subset
of chemiluminescence occurring in the biosphere as a result of biological processes is
called bioluminescence.
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To detect the luminescent signal, the luminometer, illustrated in Figure 13, uses the single
photon counting measurement technique, which is based on a photomultiplier tube
(PMT).

Figure 13: Luminometer detection system.

The luminescence system consists of the following parts: luminescence fiber
bundle, filter wheel, and PMT detector. The luminescence fiber bundle guides the light
from the sample, to the filter wheel, and finally to the detector. The filter wheel has six
filter positions better isolate the analytical signal. The photon counting module (PCM) is
designed to amplify and quantify the amount of light. Therefore, a photon of radiation
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entering the tube strikes the cathode of the PCM, causing the emission of several
electrons. These electrons are accelerated towards the first dynode. The electrons strike
the first dynode, causing the emission of several electrons for each incident electron.
These electrons are then accelerated towards the second dynode, to produce more
electrons which are accelerated towards dynode three and so on. Eventually, the electrons
are collected at the anode. Luminescence is read from the top of the well and collects as
much light as possible, in order to maximize the luminescent signal. The signals from the
detector are then digitalized with a computer.

3.2 Fluorescence polarization and detection
Fluorescence polarization measures the changes in the orientation of plane
polarized light brought about by fluorophores that undergo rapid molecular motion
during their fluorescence lifetime[29, 30]. (Figure 14)
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Figure 14: Fluorescence Polarization Assay principle [31]
The lifetime of fluorescence is the period of time between absorption of an
excitation photon and the emission of a photon through fluorescence[30, 32].
Monochromatic light is passed through a polarization filter to generate polarized
monochromatic light. The light absorbed and emitted by big fluorescent molecules
remains mostly polarized and enters another parallel and perpendicular polarized
emission filter detecting a high fluorescence polarization (FP) signal. In the contrary, a
small fluorescent molecules depolarize light and a low FP signal is detected after a
parallel and perpendicular emission filter.
For the detection of FP we were using a multi-plate reader Tecan M1000. Here,
light from the light source enters the monochromator through the entrance slit (Figure
15).
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Figure 15: Fluorescence detection

The light beam is then collimated, and then strikes the dispersing element at an
angle. The beam is split into its component wavelengths by the grating. Radiation of only
a particular wavelength leaves the monochromator through the exit slit. The light then
goes to the reading chamber and is reflected to the sample. Once the light interacts with
the sample it is guided by the fiber bundle to the PMT detector.

3.3. The VDR-Coregulator FP assay
Fluorescence polarization (FP) was used to quantify the inhibition of the
interaction between VDR-LBD and its coactivator protein SRC2-3 (Figure 16).[29]

Figure 16: Cartoon of fluorescent polarization assay used to screen inhibitors

The fluorescently labeled peptide SRC2-3 molecule free in solution is excited with
monochromatic polarized light at a wavelength of 635 nm. Due to its small molecular
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weight, the molecule tumbles rapidly in the solution causing the emission at 685 nm of
depolarized light thus a low amount of polarized light can be detected after applying a
parallel and perpendicular filter. When the MBP-VDR-LBD protein binds to the ligand
LG190178, the ligand-receptor complex can recruit the fluorescently labeled peptide
SRC2-3. Consequently, the molecular weight of the resulting complex is increased
significantly, and therefore the complex tumbles more slowly. It causes more emitted
light to remain polarized in the same plane as the excitation plane. Therefore a high
polarization signal is detected after applying a parallel and perpendicular filter allowing
the detection of a ligand-binding to a larger macromolecule. For this assay, VDR-LBD
was expressed as a MBP analog in E. coli and purify by affinity chromatography.[33]
The coregulator peptide SRC2-3 was used because it exhibited the highest affinity
towards VDR.[33] The coregulator peptide SRC2-3 was labeled with a far red
AlexaFluor 647 dye to reduce the background fluorescence due to compound
aggregation. In order to enable binding between VDR and SRC2-3, a synthetic analog of
vitamin D referred to as LG190178[34] was used, which was identified by Ligand
Pharmaceuticals[35] . The structure is shown in (Figure-17).
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Figure 17: LG190178: Synthetic Agonist for Vitamin D Receptor.
All reagent were incubated in a volume of 0.02 ml in the presence of compound in a
black 384-well plate and FP was read after 1 hour of incubation. The data was analyzed
with GraphPrism.

3.4 The VDR-mediated transcription assay
The ability of VDR antagonists to inhibit VDR-mediated transcription were measured
in commercially available embryonic renal cells (Hek 293T). Hek 293T cells contain,
the simian vacuolating (SV) virus 40 T-antigen that allows for episomal replication of
transfected plasmids containing the SV40 origin of replication. This allows for
amplification of transfected plasmids and extended temporal expression of the desired
gene products. This cell line is highly transfectable and grows, fairly easily, making it
greatly valuable for these studies.
Two vectors, VDR-CMV, a chimeric vector bearing VDR under control of a
cytomegalovirus promoter, and a second vector, 24OH luciferase, containing luciferase
under control of a the 24OH promoter, were transfected into the Hek 293T cells. The
luciferase reporter vector allows the quantification of VDR-mediated gene transcription,
because 24OH is a VDR target gene (Figure 18).
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Figure 18: 24OH luciferase plasmid vector [36]
The binding between VDR and the 24OH luciferase plasmid results in the
expression of luciferase enzyme that catalyzes a bioluminescent reaction. The light
emitted from the chemical reaction is directly proportional to the amount of expressed
enzyme, and thus, the transcriptional activity of VDR. After 18 hours, the cells are lysed
and the substrate of luciferase, luciferin, is introduced into the cellular extract along with
Mg and excess ATP (Figure 19).
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Figure 19: Enzymatic reaction of luciferase.
The luciferase enzyme acts on luciferin in the presence of magnesium cations and
oxygen. The oxidation of luciferin releases energy in the form of luminescence or
light.[37] The luminescence from this chemical reaction can be read and quantified by a
luminescence reader. The amount of light detected from the cell lysate correlates directly
with the inhibition of binding between VDR and coactivators, an interaction which is
essential for VDR-mediated transcription.

3.5 Toxicity assay
The cytotoxicity of VDR antagonists was determined by luminescence using Cell
Titer-Glo reagent (Promega). The cytotoxicity assay allows for the determination of the
number of viable cells in culture based on quantification of the ATP present, an indicator
of metabolically active cells. The toxicity assay procedure involves adding the single
reagent Cell Titer-Glo Reagent directly to cell culture. The Cell Titer-Glo reagent
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contains a surfactant, which causes cell lysis for ATP liberation. The APT is converted by
an enzymatic reaction generating a luminescent signal that is proportional to the amount
of ATP liberated. CellTiter-Glo provides the purified luciferin and luciferase necessary to
measure ATP using a bioluminescent reaction.

3.6 Experimental procedures

3.6.1. Protocol to determine the interaction between VDR and coregulator SRC2-3
This assay was conducted in 384-well black polystyrene plates (Corning) using a
buffer [25 mM PIPES (pH 6.75) 50 mM NaCl, 0.01% NP-40, 2% DMSO, VDR-LBD
protein (0.1 µM), LG190178 (0.75 µM), and Alexa Fluor 647-labeled SRC2-3. Small
molecule transfer into a 20 µL assay solution was accomplished using a stainless steel pin
tool (V&P Scientific), delivering 100 nL of the serially diluted compound solution (1:3
dilution starting at a 10mM concentration). Fluorescence polarization was detected after
initial mixing at excitation and emission wavelengths of 650 and 665 nm (Alexa
Fluor647). Three independent experiments were conducted in quadruplicate, and data
were analyzed using nonlinear regression with a variable slope using GraphPadPrism
software.

3.6.2. Protocol to determine the VDR-mediated inhibition of transcription
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The Hek293T cells were collected from a liquid nitrogen tank and 1ml was
pipetted into a 75 cm2

cell culture flask containing 14ml of media, DMEM/High

Glucose. The media contains non-essential amino acids, 2 mM L-glutamine, 1 mM
sodium pyruvate, and 1500mg/L sodium bicarbonate. The flask is then placed in an
incubator 37°C and 5 percent carbon dioxide until they reached 80 to 90 percent
confluency.

Matrigel: The purpose of matrigel for this assay is to coat the bottom of the flask and the
384 well plates so that the cells can attach to the bottom. The solution is prepared by
taking 100mL of phenol red-free DMEM and 250 µL of Matrigel concentrate. Matrigel is
the name for a gelatinous protein secreted by mouse sarcoma. 3 ml of Matrigel solution
are added to the flask and incubate for 5 minutes. The solution is replace with growth
media followed by the addition of cells.

Trypsin: Trypsin-EDTA is the most commonly used method for passaging adherent
cells. Trypsin treatment disrupts the cell monolayer and a proteolytically cleave the
bonds between cells and cells and flask. Often gentle pipetting after trypsin treatment
dissociates all cell clumps into single cells.
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Lipofectamine: Allows the transfer of DNA into eukaryotic cells with minimum damage
to the cells or plasmid. Since DNA is a charged molecule moving it past the hydrophobic
cell membrane can be a challenge. Lipofectamine is used in lipid-based methods of
transfection. The cationic head group associates with the anionic phosphates groups on
the nucleic acids. A lipid-DNA complex can pass through the cell membrane, either by
endocytosis or by fusion with the plasma membrane.

Plus Reagent: The Plus Reagent is used for pre-complexing DNA that enhances cationic
lipid-mediated transfection of DNA into the cells.

Passaging and splitting cells: Cells could be split as early as when they are at 30%
confluency. They are passaged first by aspirating the old media and then rinsing the cells
with PBS buffer, which washes away dead cells floating on the flask. To detach the cells
that were attached to the flask, by using 0.05 percent trypsin and incubating the flask for
5 minutes at 37°C and 5 percent carbon dioxide incubator. After 5 minutes, the cell
suspension was mixed by pipette in order to achieve a single cell suspension. Cells are
split into 3 new flasks. 3 ml of Matrigel is first pipetted into the new flasks and incubated
at 37°C degree for 5 minutes. The matrigel is aspirated out and 14 ml of the growth
media, DMEM/High Glucose (Hyclone, catalog no. SH3028401), nonessential amino
acids, sodium pyruvate (1mM), HEPES (10 mM), penicillin and streptomycin, and 2%
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charcoal-treated FBS (Invitrogen, catalog no. 12676-011);1ml of the cells in trypsin is
added to each flask.

VDR Transfection: When the cells reach about 80% confluency, 2 mL of untreated
DMEM containing 1.2 µL of VDR-CMV (649.7 nm/µL) thus 0.78 µg; 5.1 µL of 24OHluciferase (514.2 ng/ µL) thus 15.6 µg, and 25 µL of Plus Reagent were added and
incubated for 5 minutes at room temperature. After the 5 minutes, 75 µL Lipofectamine
was added and the mixture was incubated for 30 minutes on the shaker at room
temperature. The mixture was then added to the flask containing the cells and incubated
overnight. After 18h, 3mL of 0.05% trypsin (Hyclone, catalog no. SH3023601) was
added and the mixture was incubated so that the cells were completely detached from the
bottom of the flask. After converting the mixture into a single cell solution by pipetting
up and down a few times. The trypsinized cells were added to 12 mL of DMEM/High
Glucose (Hyclone, catalog no. SH3028401), nonessential amino acids, sodium pyruvate
(1 mM), HEPES (10 mM), penicillin and streptomycin, and 2% charcoal-treated FBS
(Invitrogen, catalog no. 12676-011), and spun down for 2 min at 1000 rpm. The media is
removed leaving behind the pellets at the bottom. The cell were re-suspended in the same
medium and diluted to 16 ml. 20 µL of Matrigel was added into rows of white clear
bottom 384-well plates and incubate at 37°C for 5 minutes. The Matrigel solution is
removed from 384 well plate and 20 µL of the cell solution was added to specific rows on
the plate. The plates are, centrifuged and incubated for five hours. After the 5 hours,
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compounds and control plates were added to cells using the Pintool (2x transfer of
compounds and 1x transfer of control plate) and incubated for 18 hours. Controls are,
DMSO (negative) and cell with were not treated with agonist calcitriol. After the 18
hours, the Bright Glo luciferase reagent was warmed up and 20 ul of it was added to each
well containing the cells. After a quick shake on a shaker and centrifugation at 1000 rpm
for one minute the plate was incubated for 20 minutes. Luminescence was measured
using Tecan M1000 and % inhibition was determined using the controls.

3.6.3. Protocol to determine the PPAR𝜹-mediated inhibition of transcription
The assay for the PPAR𝛿 was performed the same way as the VDR-mediated
transcription assay except, 1500ng of PPARδ GAL4 (814.4 ng/ µL) and 16,000ng
GAL4REluc (543.1 ng/µL) were added. The same amount of Plus Reagent and
Lipofectamine were used. On the control plate, GW7647 (30 nM), a PPARδ agonist, was
used as a positive control and DMSO was used as a negative control.[38]

Preparation of drug plates: The compound plate was prepared by first dissolving the
compound in DMSO to get 10mM solution. 90 µL of 10 mM solution of the small
molecule was put in the first well of a 96-well plate and a 1:3 dilution was made in
DMSO filling rows 1 to 10. Using the multi-channel pipette, 20 µL of serial diluted small
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molecule were pipetted to 384 well opaque drug plate filling rows 1 to 20. The
experiment was done in quadruplets A1, A2, B1, B2; all have the same concentration. A
second 384-well polystyrene plate, the control plate, had calcitriol on wells 1-20 and
positive and negative controls. DMSO was the negative control for the antagonist assay.
For the agonist assay, the control plate had DMSO as a positive control and calcitriol as a
negative control.

3.6.4

Protocol to determine the viability of cells
Hek 293T cells were also used for this assay and were cultured, plated, and

drugged in the same manner as described in the transcription assay chapter. Cells were
plated the same way in a 384 well plate. After 5 hours the compound and control were
added to the cells and incubated at 37 °C for 18 hours. To perform the luciferase assay,
20 µL of the Cell Titer-Glo reagent was added to each well of the 384-well plate that
contained the cells using a multi-channel pipette. The plate was centrifuged for 2 minutes
at 1,000 rpm and allowed to sit for 20 minutes. The Tecan Infinite M-1000 multi-label
reader was used to measure the amount of luminescence generated from each well.
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CHAPTER IV
4.

SUMMARY OF RESULTS

4.1

BF050813G
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Figure 20: Summary of BF050813G; A) FP; B) VDR-mediated transcription (antagonist
mode); C) Toxicity; D) PPARδ-mediated transcription (agonist mode)

The FP assay, BF050813G did not show a significant change in signal and hence
no IC50 values were calculated (Figure 20A). However, VDR-mediated transcription was
inhibited (significant decrease in the luminescence) at higher concentrations with an IC50
value of 43 µM (Figure 20B). In addition, there was also no signal change for the PPARδ
activity (Figure 20D), and toxicity assays (Figure 20C).

4.2

BF040813F
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Figure 21: Summary of BF040813F; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Compound BF040813F showed activity towards VDR in both, the fluorescence
polarization assay (Figure 21A) and VDR-mediated transcription assay (Figure 21B),
with IC50 ~4.37 µM and IC50 = 13.96 ± 3.54 µM, respectively. BF040813F is not toxic
and is not active as PPARδ agonist (Figure 21C & D).

4.3

BF060813H
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Figure 22: Summary of BF060813H; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

BF060813H is active in fluorescence polarization assay with an IC50 of ~5.6 µM
(Figure 22A). The activity in cells for the VDR-mediated transcription assay is IC50 =
32.57 ±7.55 µM (Figure 22B). BF060813H is nontoxic and is not able to activate
PPARδ-mediate transcription (Figure 22C&D).

4.4

BF090713B
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Figure 23: Summary of BF090713B; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Although activity is observed for BF090713B in the VDR FP assay a non-linear
regression was not possible due to missing data points at higher concentrations (Figure
23A). The IC50 value for the VDR-mediated transcription study was 38.31 ± 19.39 µM
(Figure 23B). BF090713B is nontoxic (Figure 23C) and has no agonistic activity with
PPARδ (Figure 23D).

4.5

BF090613C
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Figure 24: Summary of BF090613C; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

The IC50 values could be calculated accurately for compounds BF090613C in the
transcription assay, which was 20.87 ± 10.13 µM (Figure 24B). However, as mentioned
above, the accurate calculation of the IC50 values was not possible for the fluorescence
polarization assay due to insufficient data (Figure 24A). Compound BF090613C also
showed toxicity between 30 µM and 100 µM (Figure 24C). Compared to the previously
described compounds, this compound has shown the highest toxicity. There was no
transcriptional activation of the PPARδ (Figure 24D).
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4.6

BF090813A

Figure 25: Summary of BF090613C; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Compound BF090813A is a VDR antagonist indicated by both the fluorescence
polarization (Figure 25A) and VDR-mediated transcription assay (Figure 25B) with an
IC50 values of 19.63 ± 6.08 µM and 32.57± 7.55 µM respectively. BF090813A did not
show toxicity at the concentrations tested (Figure 25C) but showed a partial agonist
behavior with PPARδ.
BF090813A (Figure 25A).

8% activity was observed at concentration of 100 µM
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4.7

BF090712D

Figure 26: Summary of BF090712D; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Compound BF090712D shows activity at higher concentrations in the
fluorescence polarization assay but an IC50 value calculation was not possible due to
insufficient data (Figure 26A). The transcription assay (Figure 26B), however, shows
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the compound is an antagonist with an IC50 value of 6.54 ± 1.7 µM. This compound is
also nontoxic as most of the other analogues (Figure 26C). BF090712D is able to
activate transcription mediated by PPARδ. There is 32% activity at 0.5 µM in comparison
with PPARδ agonist GW7647 (Figure 26D).

4.8

BF090713B1

Figure 27: Summary of BF090613B1; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)
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Compound BF090713B1 is a VDR antagonist as determined by the FP and transcription
assays. IC50 values determined for both assays are very similar, 22.0 ± 9.99 µM and 21.27
± 3.19 µM for the FP (Figure 27A) and transcription assays (Figure 27B), respectively.
This compound was also determined to be nontoxic at the concentrations tested (Figure
27C). There was also no activity with PPARδ (Figure 27D).

4.9

BF090613C1

Figure 28: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)
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Compound BF090613C1 is active in the VDR FP assay and the VDR mediated
transcription assay. The IC50 value in the FP assay (Figure 28A) is 7.5 ± 3.41 µM and the
IC values of the transcription assay (Figure 28B) is 34.50 µM. BF090613C is not toxic
(Figure 28C) and is not able to activate PPARδ-mediated transcription (Figure 28D).

4.10

BF090813A1
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Figure 29: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Compound BF090813A1 is active in the FP assay (IC50 = 9.4 ± 3.44 µM) (Figure
29A) and in the transcription assay (Figure 29B) (IC50 = 21.06 ± 7.2 µM). This VDR
antagonist is nontoxic (Figure 29C). In terms of agonistic activity with PPARδ, there is
8% activity at 40 µM (Figure 29D).

4.11

F090812E
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Figure 30: Summary of BF090613C1; A) FP; B) VDR-mediated transcription (antagonist
mode); C) toxicity; D) PPARδ-mediated transcription (agonist mode)

Compound BF090812E is also an antagonist of VDR as determined by the FP and
Transcription assays. IC50 values determined for both assays are very similar, 12.2 ± 6.8
µM (Figure 30A) and 14.4 ± 10.2 µM (Figure 30B) for the FP and transcription assays,
respectively. This compound was also determined to be nontoxic at the concentrations
tested (Figure 30C). In addition, minor PPARδ activity (Figure 30D) was detected with
an activation of 19% in comparison with agonist GW7647 at concentration of 10 µM.
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CHAPTER V
5.

DISCUSSION AND CONCLUSIONS

In total, 11 compounds were investigated with respect to their ability to bind VDR
and inhibit the recruitment of coagulators. The design of the compounds was based on the
scaffold of GW0742, a potent PPARδ agonist, substituting the thiazole moiety with a
phenyl ring. The compounds also exhibit a different connectivity of the two moieties of
the GW0742 scaffold, which was realized with the thiazole-phenyl switch. The goal of
this research was, in respect to GW0742, to improve the affinity towards VDR and
reduce the agonistic effects towards PPARδ.
The activity of compounds was measured with a biochemical FP assay that
determines the inhibition of VDR binding to coregulator peptide SRC2-3. All of the
scaffolds demonstrated the ability to inhibit the VDR-SRC2-3 interaction. The
compounds were also tested towards their ability to bind unliganded VDR and enable the
recruitment of SRC2-3 in an agonist mode. None of the compound were VDR agonists
(results not shown). On the other hand, they all show some level of inhibition in the
antagonist mode. The most active inhibitor was compound BF060813H, a precursor for
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the final compound BF090813A1, which is an active VDR antagonist as well. The other
precursors BF050813G and BF060813H had a much lower activity. The final carboxylic
acid compounds BF090813A1, BF090713b1, and BF090613C1 bearing a methoxy
substituent were significantly more active than the corresponding methyl ester
compounds BF090713B, BF090613C, and BF090813A.
In addition, all compound were investigated using a VDR-mediate transcription
assay. In cells, the inhibition of VDR-coactivator interactions will result in the inhibition
of transcription; in this case the transcription of the luciferase enzyme. Among the
precursor compounds BF060813H, which also exhibited high activity in the FP assay was
able to inhibit VDR-mediated transcription in cells with an IC50 value of 4.3 µM. The
other precursors BF050813G and BF060813H were less active. The methyl ester
compounds BF090713B, BF090613C, and BF090813A, similar to the results of the FP
assay, were less active than the final carboxylic acid compounds. The methyl ester
BF090712D, however, exhibited a high activity in the cell-based assay but weak activity
in the FP assay. In addition, we observed a decreasing cell viability at higher
concentration of BF090712D, which in addition to inhibition of transcription will lower
the luminescence signal due to the decreased amount of viable cells. All final products
BF090813A1, BF090713b1, BF090613C1, and BF090812E showed a good activity in
the transcription assay without any signs of toxicity. Compound BF090812E was the
most active among these final compound with an IC50 of 14.4 µM.
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Because these compound were structurally derived from GW0742, a PPARδ
agonist, the activity of all compounds towards PPARδ was determined. Only three
compounds showed a partial activity towards PPARδ, which include BF090813A,
BF090712D, and BF090812E. The methyl ester BF090712D was the most potent PPARδ
agonist with an IC50 value of around 1 µM and an activation of almost 50% in respect to
GW7647. The methyl ester BF090813A was significantly less active than BF090712D
with an 8% activity in respect to GW7647 at 100 µM. Finally, BF090812E, bearing a
hydroxymethyl group instead of a methoxy group is the only final compound that
activated PPARδ transcription at a level of 19% at 100 µM.
Overall a series of new VDR antagonists were generated and evaluated using
several biochemical and cell-based assays. The introduction of a 2-methoxy group
minimized the activity of the final compounds towards PPARδ, which was confirmed by
the elevated PPARδ activity of 4-hydroxy substituted compounds BF0908122E. The
methyl ester compounds were generally less active in the FP assay than in the cell-based
assay, which might have to do with the poor solubility but good permeability of these
compounds. BF090813A1 was the most active compounds towards VDR without
residual activity towards PPARδ. Surprisingly, among the precursor compounds,
BF040813F exhibited a similar VDR activity and selectivity than BF090813A1. The
synthesis of BF040813F, in comparison with BF09081A1, is shorter and the molecule
can be produced in a higher yield. A possible continuation of this program might use
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BF040813F as parent compound and investigate the ability of compounds similar to
BF040813F to inhibit VDR-mediated transcription.

CHAPTER VI
1. SUMMARY OF DATA

Table 1: Summary of the compounds tested, with respect to their ability to inhibit VDRmediated transcription, VDR-SRC2-3 interaction (FP assay), as well as their
cytotoxicity. All results are given in micromolar concentrations.
VDR-SRC2-3

Inhibition of

Transcription

VDR-Mediated

Assay: PPARd

IC50 Values

Transcription

Agonist (EC50)

(µM)

IC50 Values

µM

interaction
Structure and ID

(µM)

Toxicity (LD50)
µM
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Low activity

43.19

No Activity

4.37

13.96

No Activity

5.6

32.57

No Activity

Low activity

38.31

No Activity

Low activity

20.87

No Activity

Non-Toxic

Non-Toxic

Non-Toxic

Non-Toxic

Toxic

at 100 uM

19.63

32.57

8% activity

Non-Toxic
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Low activity

6.54

32 % activity

Non-Toxic

9.40

21.06

No Activity

Non-Toxic

22.00

21.27

No Activity

Non-Toxic

7.5

34.5

No Activity

Non-Toxic

12.20

14.45

19%

Non-Toxic
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